SkinBioTherapeutics (LON:SBTX) Posts Quarterly Earnings Results

SkinBioTherapeutics (LON:SBTX) released its quarterly earnings data on Wednesday. The company reported GBX (0.46) (($0.01)) EPS for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

SkinBioTherapeutics Stock Down 0.4 %

Shares of LON:SBTX traded down GBX 0.10 ($0.00) during midday trading on Friday, reaching GBX 24 ($0.31). 575,179 shares of the company were exchanged, compared to its average volume of 817,032. The firm has a market cap of £54.82 million, a PE ratio of -14.76 and a beta of 2.01. The company has a quick ratio of 10.01, a current ratio of 0.93 and a debt-to-equity ratio of 27.57. SkinBioTherapeutics has a fifty-two week low of GBX 8.32 ($0.11) and a fifty-two week high of GBX 26.45 ($0.34). The stock has a fifty day simple moving average of GBX 20.16 and a two-hundred day simple moving average of GBX 16.70.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.